Matches in Nanopublications for { ?s ?p "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- _4 value "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" provenance.
- _4 value "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" provenance.
- _4 value "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" provenance.
- _4 value "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" provenance.
- _4 value "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" provenance.
- _4 value "Flavopiridol (L-868275) is one of only two CDKIs to reach human clinical trials. It is a synthetic flavone, derived from the flavonoid rohitukine. It achieves antitumor activity through a variety of mechanisms, including inhibition of cell growth and proliferation, induction of apoptosis, and inhibition of angiogenesis. This agent is a broad spectrum phosphokinase inhibitor with the strongest activity against CDKs (specifically CDK1, CDK2, CDK4, CDK6, and CDK7), although interactions with the EGFR family of receptors, receptor associated protein kinases, and protein kinase C have also been reported" provenance.